ALCHEMIA SHARES PLUNGE

ALCHEMIA SHARES PLUNGE

SHARES in Alchemia (ASX:ACL) have dived 83 per cent after the company announced its metatastic colorectal cancer trial had failed.

The treatment tested Alchemia’s HyAct technology formulated with chemotherapeutic drug irinotecan over using irinotecan alone.

HA-irinotecan did not improve progression free survival in patients.

Alchemia CEO Thomas Liquard says the company will conduct an in-depth review of the trial.

“We are extremely disappointed in the outcome of this trial and extend our appreciation to trial investigators, the clinical sites and the hundreds of patients who participated in this study,” Liquard says.

“We expect to report back to the scientific community and the market with further details on our data reviews and corporate strategy early in 2015.”

The drug development company’s financial position includes $8.9 million in cash and a $6.5 million research and tax development tax incentive to be received next month.

ACL is trading at $0.098 per share.

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

Advertisement

Related Stories

Australia orders 25 million COVID-19 vaccine doses from Moderna

Australia orders 25 million COVID-19 vaccine doses from Moderna

Biotechnology company Moderna (Nasdaq: MRNA) has entered into a n...

The pressure is on for Australia to accept the coronavirus really can spread in the air we breathe

The pressure is on for Australia to accept the coronavirus really can spread in the air we breathe

More than a year into the pandemic, the World Health Organization...

Qantas delays planned resumption of international flights to late December

Qantas delays planned resumption of international flights to late December

With the exception of flights to and from New Zealand, Australian...

Cybersecurity is a business risk, not an IT problem

Cybersecurity is a business risk, not an IT problem

A cyber attack on a business is about more than technology. The ...